Literature DB >> 21567930

Interstitial deletion 5q14.3q21.3 with MEF2C haploinsufficiency and mild phenotype: when more is less.

Vijay Tonk1, Jee Hong Kyhm, Caro E Gibson, Golder N Wilson.   

Abstract

An 18-year-old female with mild mental disability (global IQ 69), febrile seizures with subsequent myoclonic/grand mal epilepsy, and subtle morphologic changes is described with del 5(q14.3q21.3) by karyotype and minimal DNA deletion of 21.08 Mb by array comparative genomic hybridization microarray analysis (arr chr5:83,592,798-104,671,993 X1) that encompasses at least 50 genes. Included in the deletion interval is the MEF2C gene that usually causes severe mental disability when haploinsufficient, illustrating the complexity of clinic-cytogenetic correlation even with defined segmental aneuploidy. Interaction of MEF2C with the deleted febrile seizure (FEB4) and juveline myoclonic epilepsy (EJM4) loci plus the G-protein receptor (GPR98/MASS1/Usher syndrome) gene may moderate the phenotype, perhaps through common regulation by calcium.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21567930     DOI: 10.1002/ajmg.a.34012

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  6 in total

1.  MEF2C Haploinsufficiency features consistent hyperkinesis, variable epilepsy, and has a role in dorsal and ventral neuronal developmental pathways.

Authors:  Alex R Paciorkowski; Ryan N Traylor; Jill A Rosenfeld; Jacqueline M Hoover; Catharine J Harris; Susan Winter; Yves Lacassie; Martin Bialer; Allen N Lamb; Roger A Schultz; Elizabeth Berry-Kravis; Brenda E Porter; Marni Falk; Anu Venkat; Rena J Vanzo; Julie S Cohen; Ali Fatemi; William B Dobyns; Lisa G Shaffer; Blake C Ballif; Eric D Marsh
Journal:  Neurogenetics       Date:  2013-02-07       Impact factor: 2.660

2.  The MEF2C-Related and 5q14.3q15 Microdeletion Syndrome.

Authors:  M Zweier; A Rauch
Journal:  Mol Syndromol       Date:  2012-04-16

3.  Variable paralog expression underlies phenotype variation.

Authors:  Raisa Bailon-Zambrano; Juliana Sucharov; Abigail Mumme-Monheit; Matthew Murry; Amanda Stenzel; Anthony T Pulvino; Jennyfer M Mitchell; Kathryn L Colborn; James T Nichols
Journal:  Elife       Date:  2022-09-22       Impact factor: 8.713

4.  NitroSynapsin therapy for a mouse MEF2C haploinsufficiency model of human autism.

Authors:  Shichun Tu; Mohd Waseem Akhtar; Rosa Maria Escorihuela; Alejandro Amador-Arjona; Vivek Swarup; James Parker; Jeffrey D Zaremba; Timothy Holland; Neha Bansal; Daniel R Holohan; Kevin Lopez; Scott D Ryan; Shing Fai Chan; Li Yan; Xiaofei Zhang; Xiayu Huang; Abdullah Sultan; Scott R McKercher; Rajesh Ambasudhan; Huaxi Xu; Yuqiang Wang; Daniel H Geschwind; Amanda J Roberts; Alexey V Terskikh; Robert A Rissman; Eliezer Masliah; Stuart A Lipton; Nobuki Nakanishi
Journal:  Nat Commun       Date:  2017-11-14       Impact factor: 14.919

5.  MEF2C Hypofunction in Neuronal and Neuroimmune Populations Produces MEF2C Haploinsufficiency Syndrome-like Behaviors in Mice.

Authors:  Adam J Harrington; Catherine M Bridges; Stefano Berto; Kayla Blankenship; Jennifer Y Cho; Ahlem Assali; Benjamin M Siemsen; Hannah W Moore; Evgeny Tsvetkov; Acadia Thielking; Genevieve Konopka; David B Everman; Michael D Scofield; Steven A Skinner; Christopher W Cowan
Journal:  Biol Psychiatry       Date:  2020-03-31       Impact factor: 13.382

6.  Selective breeding modifies mef2ca mutant incomplete penetrance by tuning the opposing Notch pathway.

Authors:  Juliana Sucharov; Kuval Ray; Elliott P Brooks; James T Nichols
Journal:  PLoS Genet       Date:  2019-12-02       Impact factor: 5.917

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.